Central Nervous System Drugs Global Market Forecast To 2022

North America was the largest region in the global central nervous system drugs market, accounting for 43% of the market in 2018. Asia Pacific was the second largest region accounting for 24% of the global central nervous system drugs market. Africa was the smallest region in the global central nervous system drugs market.

Pharmaceutical companies are partnering with technology companies and incorporating wearables in clinical studies and for research and development of CNS disease treatments. These wearable devices make use of sensors to detect early symptoms of Parkinson’s disease such as tremors, slowness and stiffness in patients. Researchers use this data to gain insights about the disease and potential drug reactions, and thus reduce the time for trials by 30% to 50%. For instance, in 2017, Michael J. Fox Foundation for Parkinson’s Research collaborated with specialty drugmaker Cynapsus Therapeutics and Intel to integrate wearable technology in a Phase-III clinical trial of APL-130277, an experimental drug for Parkinson’s disease. Biogen, a leading CNS drugmaker is using Fitbit, a smart wearable tracker, to better understand multiple sclerosis in patient studies, and the technology is expected to extend in Alzheimer’s disease research.

Tags: Global Central Nervous System Drugs Market, Global Central Nervous System Drugs Market Analysis, Global Central Nervous System Drugs Market Overview, Global Central Nervous System Drugs Market Research Report